摘要
目的:评价奥氮平治疗难治性精神分裂症的疗效及安全性。方法:将76例难治性精神分裂症患者随机分为研究组和对照组,分别给予奥氮平和氯氮平治疗12周,采用PANSS量表和TESS量表评定疗效和不良反应。结果:奥氮平治疗前后PANSS减分率38.05%,有效率68.42%;氯氮平治疗前后PANSS减分率36.58%,有效率60.53%。奥氮平组未见严重的不良反应。结论:奥氮平和氯氮平治疗难治性精神分裂症均有良好疗效,奥氮平的不良反应少,病人依从性好。
Objective ：To evaluate＇ the efficacy and safety of Olanzapine in the treatment of treatment -resistant schizophrenia. Methods：A total of 76 patients with treatment -resistant schizophrenia were randomly assigned to the Olanzapine group and the Clozapine group for 12 weeks of treatment. The efficacy and side effects were measured with Positive and Negative symptom Scale （PANSS） and Treatment Emergent Symptom Scale （TESS）. Results： The reducing rates of PANSS total score in the Olanzapine group and the Clozapine group were 38.05% and 36.58% respectively and the effective rates were 68.42% and 60. 53% respectively. No severe side effect was found in the Olanzapine group. Conclusions ： Olanzapine and Clozapine are both effective for treating treatment - resistant schizophrenia. Olanzapine has fewer side effects and good compliance.
出处
《中国民康医学》
2007年第23期1021-1022,共2页
Medical Journal of Chinese People’s Health
关键词
奥氮平
氯氮平
难治性精神分裂症
Olanzapine
Clozapine
Treatment - resistant schizophrenia
